Brokerage Firm Rating Update on Sangamo BioSciences (SGMO)

Sangamo BioSciences (SGMO) : 6 analysts are covering Sangamo BioSciences (SGMO) and their average rating on the stock is 1.33, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Sangamo BioSciences (SGMO) : The highest level Sangamo BioSciences (SGMO) is projected to reach is $30 for the short term and the lowest estimate is at $8. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $15.25 and the possibility the share price can swing is $10.18.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Janney Capital downgrades the rating on Sangamo BioSciences (NASDAQ:SGMO). The brokerage firm has issued a Neutral rating on the shares. The shares were previously rated Buy. The rating by the firm was issued on August 4, 2016.

Sangamo BioSciences (NASDAQ:SGMO): The stock opened at $4.49 and touched an intraday high of $4.6094 on Wednesday. During the day, the stock corrected to an intraday low of $4.48, however, the bulls stepped in and pushed the price higher to close in the green at $4.54 with a gain of 0.89% for the day. The total traded volume for the day was 642,838. The stock had closed at $4.5 in the previous trading session.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.